Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
  • Reductions in mortality for lung, female breast, prostate, and colorectal cancers accounted for 60 to 80 percent of the total decrease in all cancer deaths since the early 1990s.  
  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.